Skip to main content
. Author manuscript; available in PMC: 2011 Aug 1.
Published in final edited form as: Drug Alcohol Depend. 2010 Apr 13;110(3):200–207. doi: 10.1016/j.drugalcdep.2010.02.022

Figure 1.

Figure 1

Cost-effectiveness acceptability curves for number of drug-free specimens provided during treatment (a), and longest duration abstinent (LDA) during treatment (b). For a given threshold value, the probability that CBT4CBT is cost effective is equivalent to the proportion of the 2,000 bootstrapped replicates for which CBT4CBT had the highest net benefit (Fenwick et al., 2001).